Patent details

Basic Information

Publication number:

EP2882751

PCT Application Number:

US2013052721

Type:

European Patent Granted for LU

Legal Status:

Lapsed

Application number:

EP137455549

PCT Publication Number:

WO2014022390

First applicant's nationality:

Translation Language:

EPO Publication Language:

English

English Title of Invention:

DEUTERATED IBRUTINIB

French Title of Invention:

IBRUTINIB DEUTÉRÉ

German Title of Invention:

DEUTERIERTES IBRUTINIB

SPC Number:

Dates

Filing date:

30/07/2013

Grant date:

27/06/2018

EP Publication Date:

17/06/2015

PCT Publication Date:

06/02/2014

Claims Translation Received Date:

Translations Received Date (B1 EP Publication):

Translations Received Date (B2 EP Publication):

Translations Received Date (B3 EP Publication):

Publication date:

27/06/2018

EP B1 Publication Date:

27/06/2018

EP B2 Publication Date:

EP B3 Publication Date:

Lapsed date:

30/07/2018

Expiration date:

30/07/2033

Renunciation date:

Revocation date:

Annulment date:

Owner

From:

20/06/2018

 

 

Name:

Concert Pharmaceuticals Inc.

Address:

99 Hayden Avenue, Suite 500, Lexington, MA 02421, United States (US)

Inventor

1

Name:

MORGAN, Adam, J.

Address:

United States (US)

2

Name:

TUNG, Roger, D.

Address:

United States (US)

Priority

Priority Number:

201261677307 P

Priority Date:

30/07/2012

Priority Country:

United States (US)

Classification

IPC classification:

A61K 31/519; C07B 59/00; C07D 487/04;

Publication

European Patent Bulletin

Issue number:

201826

Publication date:

27/06/2018

Description:

Grant (B1)

Annual Fees

Annual Fee Due Date:

Annual Fee Number:

Expected Payer:

Last Annual Fee Payment Date:

Last Annual Fee Paid Number:

Payer:

Filing date	Document type	Number of pages
30/11/2018	Outgoing Correspondence	1